A study on the antitumoral and differentiation effects of peganum harmala derivatives in combination with ATRA on leukaemic cells

Archives of Pharmacal Research

Volumn 30, Issue 7, 2007, Pages 844-849

  Zaker, Farhad ^a   Oody, Arezo ^b   Arjmand, Alireza ^c  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Iran Blood Transfusion Organisation   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ATRA; Cytotoxicity; Harmaline; Harmine; Leukemic differentiation

Indexed keywords

EID: 34547614674     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02978835     Document Type: Article

References (26)

1. Advani, S. H., Nair, R., Bapna, A., Gladstone, B., Kadam, P., Saikia, T. K., Parekh, P. M., Gopal, R., and Nair, C. N., Acute promyelocytic leukaemia, All trans retionic acid with chemotherapy is superior to ATRA alone. Am. J. Hematol., 60, 87-93 (1999).
2. Al- Allaf, T. A., Khuzaie, R. F., Rashan, L. J., and Halaseh, W. F., Cytotoxic activity of a series of tumor cell lines with various tumor ligands. Boll. Chim. Farm., 138, 267-271 (1999).
3. Boeira, J. M., dasilva, J., Erdtmann, B., and Henriques, J., Genotoxic effect of alkaloid Harmane and Harmine asses by commet assay in mammalian cell in vitro. Pharmacol. Toxicol., 89, 287-294 (2001).
4. Brackman, D., Lund-Johansen, F., and Aarskog, D., Expression of cell surface antigens during the differentiation of HL60 cells induced by 1,25-Dihydroxyvitamin D3, retinoic acid and DMSO. Leukemia Res., 19, 57-64 (1995).
5. Cao, R., Chen, H., Peng, W., Ma, Y., Hou, X., Guan, H., Liu, X., and Xu, A., Design,synthesis and in vitro and in vivo anti tumor activities of novel beta-carboline derivatives. Eur. J. Med. Chem., 40, 991-1001 (2005).
6. Chen, Q., Choa, R., Chen, H., Hou, X., Yan, H., Zhou, S., Peng, W., and Xu, A., Antitumor and neurotoxic effects of novel Harmine derivatives and structure-activity relationship analysis. Int. J. Cancer., 114, 675-682 (2005).
7. Dover, D., New advances in the treatment of acute promyelocytic leukaemia. Int. J. Hematol., Supp II, 179-187 (2002).
8. Fenoux, P. and Degos, L., Differentiation therapy for acute promyelocytic leukaemia. N. Engl. J. Med., 337,1076-1078 (1997).
9. Hozumi, M., Fundamentals of chemo-differentiation therapy of myeloid leukaemia. Anti Cancer. Res., 14, 1175-1192 (1994).
10. Ishida, J., Wang, H. K., Bastow, K. F., Hu, C. Q., and Lee, K. H., Anti tumor agents (201) cytotoxicity of Harmine and Bcarboline analogs. Bioorg. Med. Chem. Lett., 9, 3319-3324 (1999).
11. Jahaniani, F., Ebrahimi, S. A., Rahbar-Roshandel, N., and Mahmoudian, M., Xanthomicrol is the main cytotoxic component of Dracocephalum hotschyii and a potential anticancer agent. Phytochemistry, 66,1581-1592 (2005).
12. James, S. Y., Williams, M. A., Newland, A. C., and Closton, K. W., Leukaemia cell differentiation. Cellular and molecular interaction of retinoids and Vitamin D. Gen Pharmacol., 32,143-154 (1999).
13. Miller, W. H. Jr., Molecular targets of arsenic trioxide in malignant cells. Oncologist, 7, 1-13 (2002).
14. Mosmann, T., Rapid colorometric assay for cellular growth and survival. Application to proliferation and cytotoxicity assays. J. Immunol Methods, 65, 55-63 (1983).
15. Muto, A., Kizaki, M., Kawamura, C., Matsushita, H., Funchochi, Y., Umezewa, A., Yamada, T., Hata, J., Huzomi, N., Yamato, K., Ito, M., Ueyama, Y., and Ikeda, Y., A novel differentiationinducing therapy for APL with a combination of arsenic trioxide and GM-CSF. Leukaemia, 15, 1176-1184 ( 2001).
16. Niu, C., Yan, H., Yu, T., Sun, H. P., Liu, J. X., Li, X. S., Wu, W., Zhung, F. Q., and Chen, Y., Studies on treatment of acute promyelocytic leukaemia with arsenic trioxide. Blood, 94, 3315-3324 (1999).
17. Olsson, I., Bergh, G., Ehinger, M., and Gullberg, U., Cell differentia-tion in AML. Eur. J. Hematol., 57, 1-16 (1996).
18. Peck, R. and Bollag, W., Potentiation of retinoid-induced differentiation of HL60 and U937 cell lines by cytokins. Eur. J. Cancer., 27, 53-57 (1991).
19. Lamchouri, F., Settaf, A., Cherrah, Y., Hasser, M., Zemzami, M., Arif, N., Nadori, E. B., Zaid, A., and Lyoussi, B., In vitro cell toxcicity of peganum harmala alkaloids on cancerous cell lines. Fitoterapia, 71, 50-54 (2000).
20. Slack, J. L. and Rusinlak, M. E., Current issues in manegement of APL. Ann. Hematol., 79, 227-238 ( 2000).
21. Sobhani, A. M., Ebrahimi, S. A., and Mahmoodiani, M., In vitro evaluation of human DNA topo isomerase I inhibition by peganum Harmala and its beta carolin alkaloids. J. Pharm. Sci., 5, 19-23 (2002).
22. Tallman, M. S., Nabhan, C., Feusner, J. H., and Rowe, J. M., Acute promyelocytic leukaemia. Evolving therapie strategies. Blood, 99, 759-767 (2002).
23. Terpstra, W. and Lowenberg, B., Applications of myeloid growth factors in the treatment of acute myeloid leukaemia. Leukaemia, 11, 315-327 (1997).
24. Wang, Z. G., Rivi, R., Delva, L, Kongi, A., Sheinberg, D. A., Gambacorti-Passerini, C., Gabrilove, J. L., Warrell, R. P., and Pandolfi, P. P., Arsenic trioxide induce cell death in myeloid leukaemia. Blood, 92, 1497-1504 (1998).
25. Waxman, S., Differentiation therapy in AML (non APL). Leukaemia, 14, 491-496 (2000).
26. Zaker, F., Darley, R. L., Al Sabah, A., and Burnet, A. K., Oncogenic RAS gene impair erythroid differentiation of erythroleukaemia cells. Leukaemia Res., 21, 635-640 (1997).